HMGCLL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, the HMGCLL1 gene polymorphism is a novel genetic biomarker for intrinsic sensitivity to IM therapy in CML patients that predicts DMR in this setting.